Optimizing Pharmacotherapy of Schizophrenia: Tools for the Psychiatrist

Robert J. Constantine, Sybil M. Richard, Richard C. Surles, David Medvedeff, Naakesh A. Dewan, Lonnie Mann, Janis M. Williamson, Rajiv Tandon

Research output: Contribution to journalArticlepeer-review

Abstract

The pharmacologic treatment of schizophrenia presents several challenges: 1) available treatments are incompletely and variably effective; 2) treatments take time to show their full effects; and 3) different benefits and adverse effects of treatment appear over different time frames. To aid in treatment decisions, clinicians are inundated with information that can be difficult to digest and integrate. Treatment often is provided within systems of care that limit the range of available treatment options. To preserve broad treatment options and facilitate optimal care, the State of Florida has developed a comprehensive program to provide several tools to the treating physician, and systems of care to promote optimally effective and efficient pharmacotherapy for each individual with schizophrenia. Although a formal evaluation of its effectiveness is underway, the program has been uniformly well received and considered to be very useful in helping clinicians and treatment systems efficiently provide schizophrenia patients with the best currently available pharmacologic treatment. Elements of the program and its evolution and operation are described.

Original languageAmerican English
JournalCurrent Psychosis and Therapeutics Reports
Volume4
DOIs
StatePublished - Jan 1 2006

Keywords

  • Schizophrenia
  • Clozapine
  • Olanzapine
  • Quetiapine
  • Aripiprazole

Disciplines

  • Health Law and Policy
  • Law
  • Medicine and Health Sciences
  • Mental and Social Health
  • Psychiatric and Mental Health

Cite this